Reykjavik, ICELAND, October 19, 2004 — deCODE genetics (Nasdaq: DCGN) today announced the principal results
from its Phase IIa information - rich clinical trial ™ of DG031, the company's developmental compound which is being studied for the prevention of heart attack.
Reykjavik, ICELAND, January 9, 2008 — deCODE genetics (Nasdaq: DCGN) today announced positive topline results
from its Phase IIa clinical trial for DG051, the company's leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack.
Not exact matches
Novavax says that during
Phase IIa of seasonal flu vaccine testing, which began in May, it was able in the majority of people tested to surpass the FDA's requirements for producing enough antibodies to protect the body
from the H3N2, H1N1 and B viruses — all of which were common enough a year ago to be used to develop flu vaccines for the 2008 to 2009 flu season.
At the International Society for Stem Cell Research 2017 Annual Meeting (June 14 - 17, 2017; Boston, USA), Asterias Biotherapeutics, Inc (CA, USA) will present new 9 - month efficacy and safety data
from their ongoing SCiStar
Phase I /
IIa trial of human embryonic stem cell - derived oligodendrocyte progenitor cells.
Asterias Biotherapeutics, Inc will present new 9 - month efficacy and safety data
from their ongoing
Phase I /
IIa trial for OPC - 1 in a workshop and poster presentation.
deCODE genetics (Nasdaq: DCGN) today announced positive results
from its preliminary
Phase II clinical trial (
Phase IIa) of Cephalon Inc.'s (Nasdaq: CEPH) CEP - 1347 in asthma.